LamdaGen Corporation is an innovative technology company at the forefront of developing and integrating powerful plasmonic biosensors for a wide range of applications. Our primary focus is on enabling rapid point-of-use diagnostic and detection systems that require exceptional sensitivity and precise quantitation. To achieve this, we have developed the LAuRA Digital Diagnostic System, which utilizes our proprietary plasmonic biosensors as the core technology, supported by our patented Plasmonic Amplification Technology (PAT). PAT represents a significant breakthrough in the realm of rapid, high-sensitivity detection, featuring a unique double amplification system. This technology allows our products to combine the speed and convenience of lateral flow assay (LFA) technologies with the exceptional sensitivity and quantitation capabilities of microtiter plate enzyme-linked immunosorbent assays (ELISA). As a technology holding company, LamdaGen follows a serial spin-off licensing model to optimize the value of our biosensor-based technologies. We leverage our expertise and intellectual property to expand into various sectors, including Food and Water Safety, Human Health, Animal Health, and Environmental Health. Through strategic partnerships with industry leaders in these sectors, we are applying our powerful biosensor technology to a broad range of applications, facilitating significant advancements in diagnostic capabilities and enhancing overall safety and well-being. At LamdaGen, our vision is to revolutionize the field of biosensing by consistently pushing the boundaries of sensitivity, speed, and precision for commercial use. We remain committed to delivering cutting-edge solutions that address critical needs across diverse industries, ultimately improving health outcomes and enabling more effective decision-making processes. We invite you to explore partnering opportunities with us.